Comparison of survival outcomes according of patients with metastatic gastric cancer receiving trastuzumab with systemic chemotherapy

PURPOSE: Currently, trastuzumab plus chemotherapy is the standard first-line therapy for human epidermal growth factor receptor 2 (HER2)-positive advanced or metastatic gastric cancer (mGC) or esophagogastric junction cancer. However, it is not clear whether the prognosis of HER2-positive mGC treate...

Descripción completa

Detalles Bibliográficos
Autores principales: Ha, Gi-Young, Yang, Sung-Hyun, Kang, Hye-Jin, Lee, Hyo-Lak, Kim, Jin, Kim, Yun-Ju, Yu, Hang-Jong, Lee, Jong-Inn, Jin, Sung-Ho
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Korean Society of Surgical Oncology 2020
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9942733/
https://www.ncbi.nlm.nih.gov/pubmed/36945715
http://dx.doi.org/10.14216/kjco.20011

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9942733/
https://www.ncbi.nlm.nih.gov/pubmed/36945715
http://dx.doi.org/10.14216/kjco.20011

Ejemplares similares